Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 945,237 shares, a growth of 42.3% from the October 13th total of 664,355 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 280,363 shares, the days-to-cover ratio is currently 3.4 days.
ADAP has been the topic of several research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a report on Wednesday, October 4th. TheStreet raised shares of Adaptimmune Therapeutics PLC from a “d” rating to a “c” rating in a report on Thursday, November 2nd. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Finally, BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $11.58.
Large investors have recently made changes to their positions in the business. KCG Holdings Inc. acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $133,000. Dynamic Technology Lab Private Ltd bought a new position in Adaptimmune Therapeutics PLC in the 3rd quarter valued at approximately $199,000. Paloma Partners Management Co bought a new position in Adaptimmune Therapeutics PLC in the 1st quarter valued at approximately $165,000. OxFORD Asset Management LLP bought a new position in Adaptimmune Therapeutics PLC during the second quarter worth $156,000. Finally, Virtu KCG Holdings LLC raised its stake in Adaptimmune Therapeutics PLC by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after buying an additional 26,105 shares during the last quarter. Hedge funds and other institutional investors own 68.12% of the company’s stock.
Adaptimmune Therapeutics PLC (ADAP) opened at $8.10 on Monday. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $9.29.
WARNING: “Short Interest in Adaptimmune Therapeutics PLC (ADAP) Grows By 42.3%” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/13/short-interest-in-adaptimmune-therapeutics-plc-adap-grows-by-42-3.html.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.